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Abstract: Synthetic tubulysins 24a-m, having non-hydrolysable N-substituents on tubuvaline (Tuv), were obtained in high purity 
and good overall yields using a multi-step synthesis. Key step was the formation of differently N-substituted Ile-Tuv fragments 10 
via aza-Michael reaction of azido-Ile derivatives 8 with the α,β-unsaturated oxo-thiazole 5. A SAR study using a panel of human 
tumor cell lines showed strong anti-proliferative activity for all compounds 24a-m, with IC50 values in the sub-nanomolar range, 
which were distinctly lower than those of Tubulysin A, vinorelbine, and paclitaxel. Furthermore, 24a-m were able to overcome 
cross-resistance to paclitaxel and vinorelbine in two tumor cell lines with acquired resistance to doxorubicin. Compounds 24e and 
24g were selected as leads to evaluate their mechanism of action. In vitro assays showed that both 24e and 24g interfere with 
tubulin polymerization in a vinca alkaloid-like manner and prevent paclitaxel-induced assembly of tubulin polymers. Both 
compounds exerted antimitotic activity and induced apoptosis in cancer cells at very low concentrations. Compound 24e also 
exhibited potent antitumor activity at well tolerated doses on in vivo models of diffuse malignant peritoneal mesothelioma, such 
as MESOII peritoneal mesothelioma xenografts, whose growth was not significantly affected by vinorelbine. These results indicate 
that synthetic tubulysins 24 could be used as standalone chemotherapeutic agents in difficult-to-treat cancers. 
Introduction 
Natural tubulysins 1 (Fig. 1) belong to a family of tetrapeptides isolated from myxobacterial culture extracts. They 
incorporate L-isoleucine (Ile) and three non-proteinogenic amino-acids: N-methyl-D-pipecolic acid (Mep), tubuvaline 
(Tuv), and either tubutyrosine (Tut) or tubuphenylalanine (Tup).[1] Tubulysins, which feature seven stereogenic centers 
and a peculiar N,O-acetal group on Tuv (Table 1), received a great deal of interest since their discovery, principally for 
their potent cytotoxicity (IC50values in the pico-/nano-molar range) against various human tumor cell lines, such as KB-
3.1 and KB-V1 (cervix),[1-3] HEK293T (kidney),[2] U-2 OS (bone),[2] SW-480 and HCT-116 (colon),[2,4,5] K-562 and HL-60 
(leukemia),[1,2,5,6] A549 (lung),[2,5] 1A9 (ovarian), [7] MCF-7 and MDA-MB-231 (breast).[5,7,8] 
Tubulysins are produced by several myxobacteria 
strains.[1,3] Although their biosynthetic pathway has 
not been fully elucidated yet, it has been shown that 
tubulysins are produced by a mixed nonribosomal 
peptide synthetase-polyketide synthase system.[9,10] 
All the biosynthetic routes hitherto investigated for 
producing natural tubulysins evidenced serious 
limitations, principally the low yields. Various 
synthetic approaches have thus been investigated 
for producing tubulysins in amounts sufficient for 
performing preclinical or clinical studies. Synthetic 
strategies based on the coupling of the four amino-
acids evidenced the critical issue of introducing the 
tertiary amide-N,O-acetal on the Tuv residue, along 
with its acid- and base-lability. Although solutions 
have been proposed in this sense,[11-13] to our 
knowledge none of the published syntheses has yet 
to be used to secure sufficient amounts of tubulysins 
for clinical development. Alternative strategies were 
focused on the production of simplified analogues via 
replacement of the N,O-acetal moiety with hydrogen 
(tubulysin U and V and their analogues)[7,14-17] or alkyl 
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and -CH2-O-alkyl groups.[18] A further strategy relied on the incorporation of a stable retro-amide moiety carrying a 
dipeptoid residue leading to “tubugi” derivatives [19].[19] Pre-tubulysins, having structurally simplified Tuv fragments lacking 
the OAc group, have been also proposed.[20] In general, all these modifications evidenced a much lower antiproliferative 
activity of the synthetic derivatives relative to the most potent natural tubulysins. Ultimately, IC50 (concentrations inhibiting 
cell growth by 50%) values at least two order of magnitude higher were consistently observed upon N,O-acetal ester 
replacement by a hydrogen atom.[1,15] 
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Figure 1. Chemical structures of natural tubulysins 1. R1, R2, and R3: various substituents (see Table 1). 
Table 1. Natural tubulysins 1. 
Tubulysin R1 R2 R3 
A OH CH2OC(O)CH2CH(CH3)2 C(O)CH3 
B OH CH2OC(O)CH2CH2CH3 C(O)CH3 
C OH CH2OC(O)CH2CH3 C(O)CH3 
D H CH2OC(O)CH2CH(CH3)2 C(O)CH3 
E H CH2OC(O)CH2CH2CH3 C(O)CH3 
F H CH2OC(O)CH2CH3 C(O)CH3 
G OH CH2OC(O)CH=C(CH3)2 C(O)CH3 
H H CH2OC(O)CH3 C(O)CH3 
I OH CH2OC(O)CH3 C(O)CH3 
U H H C(O)CH3 
V H H H 
X OH H C(O)CH3 
Z OH H C(O)CH3 
 
Total synthesis of modified tubulysins combined with structure-activity relationship studies allowed to define key structural 
parameters related to tubulysin cytotoxicity.[9,21-24] The Tuv carbon atoms stereochemistry as well as the presence of both 
isopropyl and acetyl group in the Tup fragment are recognised as the most important features for maximizing cytotoxicity. 
D-configuration of the stereocentre and the Mep N-alkyl substitution are other sensitive structural parameters. Minor 
effects on cytotoxicity have been instead associated with N,O-acetal moiety replacement with carbon-chains, thiazole ring 
substitution (although within few tested alternative aromatic or heteroaromatic rings), Tup stereochemistry, and the size 
of the aza-cycloalkyl moiety.[9,21-26] Moreover, a C6H4-4-OH instead of a C6H5 residue in the Tup fragment induced a weak 
cytotoxicity drop, as a likely consequence of an overall lipophilicity decrease.[9] 
Although both natural and synthetic tubulysins showed strong anti-cancer potential, to our knowledge unconjugated 
tubulysin derivatives have never been successfully used in vivo, due to their reported extremely narrow therapeutic 
windows. De facto, the tubulysin dosage and formulation used so far in in vivo experiments either induced animal death 
or showed no significant therapeutic effect.[27] 
Very interesting results have been conversely achieved when natural tubulysin derivatives were conjugated with folic acid, 
DUPA or linear β-cyclodextrin and polyethylene glycol (CDP) copolymers.[27-31] Clinical trials are currently in progress on 
conjugates of Tubulysin B hydrazides with folic acid or DUPA. Moreover, pre-clinical in vivo assays evidenced anti-tumor 
activity of CDP-TubA nanoparticles based on a thiol derivative of tubulysin A linked to CDP.[27] Tubulysin B has also been 
tested as payload in cholecystokin 2 receptors (CCK2R) small molecule ligand conjugates.[32] Tubulysin derivatives have 
been also conjugated to dendrimers as macromolecular drug carriers.[33] 
Recently, an antibody drug conjugate (ADC) based on a synthetic tubulysin analogue and HER2/neu antibody 
trastuzumab (Herceptin®) has been tested in an animal model of HER2/neu receptor expressing tumor.[34] This ADC 
inhibited tumor growth in a nude mice bearing trastuzumab-sensitive N87 tumor model and showed a dose-response 
effectiveness equivalent to that induced by 15 mg/kg of ado-trastuzumab emtansine ADC (Kadcyla®) at the dose of 60 
 
   
 
mg/kg.[34] More recently, other synthetic analogues of natural tubulysins have also been successfully tested as payloads 
in HER2-based ADCs.[35] 
To identify novel synthetic tubulysin derivatives with improved anti-tumor activity, with the aim of using them as cytotoxic 
payloads in ADCs, our group patented an innovative and scalable synthetic procedure to prepare a specific class of 
analogues with enhanced cytotoxicity relative to that of natural tubulysins.[36] Very recently, we reported on the cytotoxicity 
(IC50 in the pM range) and mechanism of action of a first lead analogue 24b (Table 2), or KEMTUB010, having a non-
hydrolysable benzyl group on the N-Tuv fragment and a Tup residue incorporating a C6H4-4-F group.[8] 
Here we provide a full account of our studies on the synthesis, structure activity relationship (SAR) and in vitro anti-cancer 
activity of the super-potent tubulysin derivatives 24a-m. Based on the SAR study on cells, a lead tubulysin derivative 
(compound 24e) was then assayed in animal models. 
Results and Discussion 
Synthesis of tubulysin derivatives 
Our aim was to increase both lipophilicity and chemical stability of the novel tubulysin analogues relative to both natural 
tubulysins 1 and known synthetic analogues. We decided to replace the N,O-acetal group on the N-Tuv fragment of 1 
with non-hydrolysable and variably hydrophobic carbon-substituents: benzyl, phenyl, -CH2-cyclo(etero)alkyls, -CH2-
eteroaryls, -CH2-CH2-O-CH3. 
To further modulate the lipophilicity of these derivatives, we decided to include in the SAR study analogues carrying either 
a phenyl or a p-fluorophenyl group on the Tup fragment. As suggested by previous SAR studies,[9,21,22] the configuration 
of the seven stereogenic centers of natural tubulysins 1 was maintained. Moreover, both isopropyl and acetyl groups in 
the Tuv fragment, as well as the N-methyl substitution of the Mep residue were also maintained in all the novel compounds. 
Table 2 shows the chemical structure of all the tubulysin derivatives 24a-m synthesized in this work. 
The synthesis of 24a-m was achieved by assembling of three fragments: Ile-Tuv (11, Scheme 2), Tup (19, Scheme 4) 
and Mep. To obtain the Ile-Tuv fragment we started from the synthesis of the thiazole ring according to previously reported 
procedures (Scheme 1).[15] L-Cysteine ethyl ester hydrochloride 2 was condensed with methylglyoxal to give the 
intermediate 2-acetyl-4-ethoxycarbonylthiazolidine 3, which was quickly dissolved in CH3CN and oxidized with MnO2 at 
65 °C to provide 2-acethylthiazole 4. Aldol condensation was carried out with thiazole 4 and isobutyraldehyde using 
catalytic TiCl4 as catalyst, affording the α,β unsaturated thiazolyl ketone 5. 
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Scheme 1. Synthesis of the α,β unsaturated thiazolyl ketone 5. Reagents and conditions: (a) methylglyoxal, NaHCO3, EtOH-H2O (1:1), overnight; 
(b) MnO2, MeCN, 65 °C, overnight (52% over two steps); (c) isobutyraldehyde, TiCl4, Et3N, anhydrous THF, from -78 °C to rt (70%). 
Next, a series of amines 6 was reacted with the enantiomerically pure azido acyl chloride derivative 7 affording the azido 
derivatives 8a-i with yields ranging from 80 to 99% (Scheme 2). 
Aza-Michael reaction of azido derivatives 8a-i with α,β unsaturated thiazolyl ketone 5 (Scheme 2) afforded β-amino 
ketones 9a-i, thus enabling the incorporation of the different N-substituents into the Ile-Tuv fragment. Derivatives 9a-i 
were obtained as diasteroisomeric mixtures, in variable ratios depending on the R1 substituent of the azido derivatives 8. 
Moderate diastereoselectivities were observed for 9b,c,d (d.r. 70:30, 75:25, 73:27), with a drop of diastereoselectivity for 
9a,g,h,i (d.r. 68:32, 63:37, 66:34, 68:32). No or very low diastereoselectivity was instead observed for 9e,f (d.r. 50:50, 
55:45). To prepare stereochemically pure Tuv fragments, we performed an asymmetric reduction of the carbonyl function 
using chiral oxazaborolidines (Corey-Bakshi-Shibata, CBS, catalyst). (S)-CBS in the presence of BH3•Me2S predominantly 
reacted with the Si face of derivatives 9a-i to give alcohols 10a-i and 10’a-i, which were easily obtained in 
diastereomerically pure form and high enantiomeric excess by flash chromatography (FC). The last step of Tuv fragment 
synthesis was carried out only on diastereisomers 10a-i, having the same configuration as the natural tubulysins, which 
were submitted to gentle hydrolysis to the corresponding carboxylic acids 11a-i (Scheme 2). 
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Scheme 2. Synthesis of the azido derivatives 8a-i. Reagents and conditions: (a) i-Pr2EtN, CH2Cl2, 0 °C, 1h, 80 to 99%; (b) KHMDS, anhydrous 
THF, -78 °C, 1h, overall 15 to 54%; (c) (S)-CBS, anhydrous THF, BH3•Me2S 10M, from 0 °C to rt, overall 32 to 81%; (d) LiOH, THF/H2O 4:1, 12h, 
rt, 60 to 99% 
The synthesis of the Tup fragment was based on the use of (−)-menthol as chiral auxiliary, which strongly facilitates the 
separation of Tup diastereomers by FC. As previously reported,[21] (−)-menthol was treated with bromoacetyl bromide to 
give compound 12 (Scheme 3). The latter was converted into the corresponding phosphonium ylide 13 by treatment with 
triphenylphosphine and subsequently with aqueous NaOH. Methylation of 13 with CH3I gave the key reagent 14. 
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Scheme 3. Synthesis of the phosphonium ylide 14. Reagents and conditions: (a) Et3N, anhydrous THF, from 0 °C to r.t., 2h; (b) PPh3, THF reflux, 
2h, NaOH 0.38N, toluene, rt; (c) MeI, CH2Cl2, from 0 °C to rt, overnight. 
Wittig olefination of ylide 14 and aldehydes 16a,b (Scheme 4), prepared by Dess-Martin periodinane oxidation of the 
corresponding Boc protected phenyl-alaninols 15a,b, gave the α,β unsaturated amino esters 17a,b in good yields. These 
compounds were hydrogenated using Pd/C (10%) in ethyl acetate to give the Tup fragment precursors 18’a,b and 18”a,b 
as mixtures of diastereoisomers, which were separated by FC (d.r. 18’a/18”a = 70/30 and d.r. 18’b/18b” = 80/20). Only 
diastereomers 18’a,b – which have the natural Tup stereochemistry - were used for the next steps of the synthesis. The 
final Tup fragments 19a,b were obtained using a two steps procedure based on: (i) simultaneous de-protection of both 
amino and carboxylic functions with 6N HCl at 130 °C to give the corresponding free amino acids as hydrochlorides; (ii) 
O-methylation to give the enantiomerically pure methyl esters 19a,b (Scheme 4).[37] 
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Scheme 4. Synthesis of stereopure 4-amino-2-methyl-5-phenylpentanoic acid 19a and 4-amino-5-(4-fluorophenyl)-2-methyl-pentanoic acid 19b 
methyl esters hydrochlorides. Reagents and conditions: (a) anhydrous THF, 0 °C, ethyl chloroformate, Et3N, 1h, NaBH4 in H2O at 0 °C, 63%; (b) 
Dess-Martin periodinane, NaHCO3, CH2Cl2, 2h, 98% for 16a, 99% for 16b; (c) CH2Cl2, from  0 °C to rt, 2h, 78% for 17a, 74% for 17b; (d) H2, Pd/C 
10%, EtOAc, overnight, overall 87% for 18a, overall 97% for 18b; (e) HCl 6N, 130 °C, 1h; (f) 2,2-dimethoxypropane, HCl 37% 2µL, MeOH, 50 °C, 
12h, 91% for 19a, 93% for 19b. 
Assembling of the final tubulysin derivatives 24a-m was achieved using conventional peptide synthesis in solution 
(Scheme 5). Coupling of the Tuv fragments 11a-i with Tup methyl ester hydrochloride derivatives 19a,b afforded the 
tripeptides 20a-m. Next, the azide function of compounds 20a-m was reduced by hydrogenation over Pd/C (10%) to give 
the amino derivatives 21a-m. These compounds were not isolated from the reaction mixtures but were directly subjected 
to coupling with Mep, affording tetrapeptides 22a-m which were isolated in good yields. The methyl ester function of 22a-
m was hydrolysed with LiOH in THF, followed by TFA treatment at pH=2 to afford compounds 23a-m, isolated as TFA 
salts. Finally, stereopure tubulysin derivatives 24a-m were obtained by acetylation of the hydroxyl function of 23a-m in 
Ac2O and subsequent neutralization with pyridine. 
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Scheme 5. Synthesis of tubulysin derivatives 24a-m. Reagents and conditions: (a) HATU, HOAt, Et3N, DMF, rt, 2h, 70 to 98%; (b) H2, Pd/C 10%, 
MeOH, overnight, 99%; (c) HATU, HOAt, Et3N, CH2Cl2, rt, 4h, 73 to 99%; (d) LiOH 1N, THF, 48h, rt, TFA pH=2, 71 to 99%; (e) Ac2O, pyridine, rt, 
overnight, 63 to 99%. 
In vitro and in vivo assays 
All the tubulysin analogues 24a-m were tested for their antiproliferative activity on human colon cancer cell line HT-29 
(Table 2). These compounds were compared to TubA; TubU,[22] and the N-Me tubulysin U derivative Me-TubU (R = Me, 
X = H in structure 24 in Table 2). All the assayed compounds showed strong cytotoxic activity, with IC50 values in the pM 
range (IC50 < 0.28 nM), which were lower than that of the reference natural tubulysin TubA (IC50 = 0.75 nM), and 
significantly lower than those of the synthetic tubulysin derivatives reported so far in the literature (IC50 values in the order 
of nM units). Particularly, 24b, 24e, 24g, 24h, 24j, and 24m, all showed IC50 values lower than 0.10 nM, being significantly 
more cytotoxic than TubA. The same trend and lower IC50 values relative to that of TubA were detected also on human 
ovarian carcinoma cell line A2780 (data not shown).  
  
 
   
 
 
Table 2. Chemical structure and HT-29 cell cytotoxicity (IC50 pmol L-1)[a] of 
the synthetic tubulysin derivatives 24. 
 
Compound R X HT-29 cell line 
24a 
 
H 112±24 
24b 
 
F 61±9 
24c 
F  
H 101±15 
24d 
 
H 225±27 
24e 
 
H 55±10 
24f 
 
F 190±12 
24g 
S  
H 82±12 
24h 
S  
F 90±15 
24i 
O  
F 183±10 
24j 
O  
F 92±13 
24k 
 
F 102±19 
24l 
O
 
H 278±25 
24m 
O
 
F 95±16 
TubA CH2OC(O)CH2CH(CH3)2 OH 752±51 
TubU H H 3780±125 
Me-TubU CH3 H 5820±198 
[a] Concentration of tested compounds able to inhibit cell growth by 50%. 
 
On this cell line, IC50 values of 24a, 24c, and 24k were comparable to those of the most cytotoxic compounds measured 
on HT-29. In general, amongst the novel series of synthetic tubulysins, no substantial effect on antiproliferative activity 
was detected upon (i) replacement of hydrogen with fluorine in position 4 of the Tup fragment benzyl moiety of series 24 
(X-residue in Table 2), and (ii) the nature of the carbon N-substituent of the Tuv residue. 
Based on the results of the preliminary screenings, representative selected compounds amongst this series were 
submitted to further tests by adopting a wider spectrum of tumor cell lines. In particular, the antiproliferative activity of 
these tubulysin derivatives was evaluated on a panel of human tumor cell lines, including colon (LoVo) and breast (MCF-
7) cancer cell lines, their derivatives selected for in vitro acquired resistance to doxorubicin (DX) and showing cross-
resistance to taxanes and vinca alkaloids (LoVo/DX; MCF-7/DX),[38,39] and on two diffuse malignant peritoneal 
mesothelioma (DMPM)[40] cell lines (STO and MESOII), established in our laboratories.[41] Exposure of cancer cells to 
increasing concentrations of tested compounds resulted in a markedly higher cytotoxic effect compared to those of two 
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microtubule-interacting agents with opposite mechanism of action (i.e. paclitaxel and the vinca alkaloid vinorelbine), used 
as reference compounds (Table 3). 
The cytotoxic effect of all the assayed tubulysin derivatives was consistently observed across all tested cancer cell lines, 
including those characterized by acquired drug resistance.[39] Reference compounds paclitaxel and vinorelbine showed 
lower antiproliferative activity compared to all the novel tubulysin derivatives, particularly relative to 24a, 24b, 24c, 24e, 
24g, and 24h. In general, these compounds showed IC50 values 1-2 order of magnitude lower than vinorelbine on MESOII, 
STO, LoVo, and MCF-7 cell lines. The comparison was even more favorable for these tubulysins if paclitaxel was 
considered as reference compound. IC50 value of 24b – or KEMTUB010 - on MCF-7 cell line was in accordance with that 
previously determined for the same compound.[37] Amongst the novel tubulysin derivatives, 24e and 24j showed 
respectively the lowest and the highest IC50 values throughout the entire panel of cell lines tested. 
The superior cytotoxic activity of these tubulysin derivatives compared to the reference compounds was confirmed in vitro 
by using cell lines with acquired resistance to doxorubicin. In fact, the tubulysin derivatives 24 showed IC50 values at least 
23 and 100 fold lower than vinorelbine and paclitaxel, respectively, on LoVo/DX cell line. Compound 24j – the less potent 
compound in the series - was 15 and 3 fold more active than vinorelbine and paclitaxel, respectively, on MCF-7/DX cell 
line. However, the cytotoxicity of all the other tubulysin derivatives 24 on this cell line was significantly higher (IC50 values 
1-2 orders of magnitude lower than 24j). 
 
Table 3. Cytotoxic activity of tubulysin derivatives (IC50 nmol L-1)[a] 
Compound 
Cell Line 
MESOII STO LoVo LoVo/DX RI[b] MCF-7 MCF-7/DX RI[b] 
Paclitaxel 13.65±0.05 11.9±5.5 313±66 11700±1100 37.3 32.4±2.3 307.2±124.7 9.5 
Vinorelbine 5.65±2.65 4.8±0.6 98.2±47.7 2355±472 23.9 7.3±2.7 65.4±10.2 8.9 
24a 0.215±0.05 0.22±0.07 1.87±1.86 1.35±0.78 0.8 0.37 ± 0.38 0.725 ± 0.39 1.94 
24b 0.5±0.003 0.525±0.07 5.4±2.7 4.5±2 0.8 0.32 ± 0.035 1.45 ± 0.07 4.53 
24c 0.25±0.07 0.11±0.12 2.5±0.7 1.55±0.07 0.62 0.425 ± 0.3 0.535 ± 0.2 1.25 
24e 0.036±0.003 0.019±0.004 0.7±0.4 2.1±0.3 3 0.44±0.22 0.41±0.07 0.93 
24g 0.31±0.15 0.24±0.08 3.1±1.2 1.4±0.2 0.45 1.56±0.54 0.98±0.41 0.63 
24h 0.47±0.11 0.37±0.14 1.9±1.1 10.5±4.9 5.5 0.74±0.03 1.08±0.39 1.45 
24j 6.5±3.5 2.8±1.1 14.2±7.1 ~100 7 4.77±0.035 22.2±4.9 4.65 
24k 1.97±0.23 1.60±0.61 7.5±4.5 60.9±10 8.12 2.75±0.26 2.97±1.6 1.08 
24m 1.08±0.49 0.94±0.62 4.2±2.8 18.1±2 4.3 1.93±0.57 5.71±3.63 2.96 
[a] Concentration of tested compounds able to inhibit cell growth by 50%; [b] Resistance index has been defined as the ratio between the IC50 
values observed in resistant (LoVo/DX and MCF-7/DX) and wild-type (LoVo and MCF-7) cells. 
 
It is important to note that the resistance index (RI), defined as the ratio between the IC50 values observed in resistant 
(LoVo/DX and MCF-7/DX) and wild-type (LoVo and MCF-7) cells, was markedly lower for all tubulysin derivatives (RILoVo/DX 
<8; RIMCF-7/DX <5) compared to paclitaxel (RILoVo/DX: 37.3; RIMCF-7/DX: 9.5) and vinorelbine (RILoVo/DX: 23.9; RIMCF-7/DX: 9.0) 
(Table 3), thus suggesting that they may be poor substrates for the drug efflux pumps. 
The potent activity of these tubulysin derivatives was also confirmed for a selected subclass on additional cancer cell 
lines, including N87 (gastric carcinoma), BT474 and SkBr3 (breast cancer) (Supporting Information, Table S1). Especially 
in the two breast cancer cell lines, the novel compounds showed significantly higher cytotoxic activity relative to TubA, 
with IC50 values at least one order of magnitude lower than those of the reference natural analogue. 
Compounds 24e and 24g were selected as lead compounds for their strong cytotoxic activity and lower RI values, 
respectively (Table 3). Their effects on microtubule assembly were investigated as the first step of the study on their 
mechanism of action. Exposure of DMPM cells to either agents, administered at a concentration corresponding to the 
specific IC80, did not result in perturbations of the intracellular pools of tubulin, as observed in cells treated with vinorelbine 
and - oppositely - in cells exposed to paclitaxel (Figures 2A and S1, Supporting Information). Similar results were obtained 
in wild-type (LoVo) and resistant (LoVo/DX) colon cancer cell lines  (Supporting Information, Fig. S2). 
 
   
 
 
Figure 2. Tubulysin derivatives alter tubulin polymerization according to a vinca alkaloid-like mechanism of action. A) Representative 
immunoblotting showing the effect on polymerized (P) and soluble (S) fractions of tubulin from DMPM cells upon a 24-h exposure to the different 
tested agents at the indicated concentrations (nmol L-1); B) Test-tube assessment of tubulin polymerization in the presence of paclitaxel (PTX), 
vinorelbine (VIN), 24e and 24g; used at the indicated concentrations (µmol L-1); C) Effect of tubulysin derivatives and vinorelbine on PTX-induced 
tubulin polymerization. A representative experiment of two is shown. UNT: untreated samples. 
The direct interference of 24e and 24g with tubulin polymerization was further evaluated by measuring the GTP-induced 
assembly of purified tubulin monomers using a test-tube assay. Tubulin polymerization was monitored over time (0-60 
min) by measuring the changes in solution turbidity at 340 nm. Results showed that tubulin polymerization was markedly 
inhibited in samples treated with 24e or 24g (1 and 10 µmol L-1, Vmax: 10±2 mOD/min) compared to untreated controls 
(Vmax: 23±1 mOD/min) (Fig 3B). Such an effect, which was similar to that observed in samples treated with equimolar 
concentration of vinorelbine (Vmax: 9±2 mOD/min), occurred soon after a 5-min exposure to each agent and persisted over 
the time course of the experiment. As expected, paclitaxel induced a pronounced increase in the polymerization rate 
(Vmax: 62±2 mOD/min) of tubulin compared to controls or samples treated with tubulysin derivative and vinorelbine (Fig. 
2B). Such a paclitaxel-induced increase in the tubulin polymerization was remarkably affected by tubulysin derivatives, 
as suggested by the complete inhibition of the reaction in samples concomitantly treated with paclitaxel and 24e or 24g 
or vinorelbine (Fig. 2C). Indeed, a ~7-fold decrease in the Vmax was observed in paclitaxel-treated cells in the presence of 
tubulysin derivates or vinorelbine compared to taxane alone (~8±3 mOD/min and 55±5 mOD/min, respectively). These 
findings further corroborate our previous observations indicating that tubulysin compounds show a typical vinca alkaloid-
like mechanism of action on tubulin dynamics. 
Since mitotic arrest is a hallmark of agents able to interfere with microtubule assembly, the capability of 24e and 24g to 
interfere with the progression of cells through the M-phase of the cell cycle was investigated. Specifically, a 24-h exposure 
of DMPM cells (Fig. 3A) to equitoxic concentrations of 24e and 24g (10 and 0.1 nmol L-1, respectively) resulted in a 
remarkable accumulation of cells (~70%) in the G2/M phase of the cell cycle, similarly to what observed upon exposure 
to equitoxic amount (30 nmol L-1) of vinorelbine or paclitaxel (Fig. 3A). Furthermore, the analysis of the expression levels 
of factors known to be involved in the mitotic arrest showed a marked accumulation of mitosis-specific phosphorylated 
epitopes recognized by MPM-2 antibody (Fig 3B), that was paralleled by a marked up-regulation of cyclin B (Fig. 3B), a 
factor that plays a pivotal role in the control of G2/M cell cycle transition.[42] 
In addition, fluorescence microscopy analysis of cells stained for MPM-2 showed the presence of 50% of mitotic cells 
within the overall cell population upon a 24-h exposure to equitoxic amounts of 24e, 24g, vinorelbine or paclitaxel (Fig. 
3C). Finally, the assessment of apoptosis by TUNEL assay showed comparable amounts of apoptotic cells, upon 
exposure to equitoxic doses of tested derivatives and reference compounds (Fig. 3C). Similar results were obtained in 
LoVo and LoVo/DX colon cancer cells (Supporting Information, Fig. S3). Overall, these findings indicate that, similarly to 
 
   
 
vinorelbine and paclitaxel, the tubulysin derivatives induced mitotic arrest and apoptosis in cancer cells of different 
histological origin, at much lower concentrations than those required to obtain comparable effects by conventional 
microtubule-interacting agents. These results confirm the preliminary data we have previously published on the effects 
induced by KEMTUB010 (24b) in a panel of breast cancer cells, particularly in MCF-7 and MDAMB231 (MDA231) cell 
lines.[8] 
 
Figure 3. A 24-h exposure to tested compounds induced mitotic arrest and apoptosis in DMPM cells. A) Flow cytometric analysis of the cell 
cycle distribution in untreated cells (UNT) and in cells exposed for 24 h to paclitaxel (PTX), Vinorelbine (VIN) and the tubulysin derivatives 24e and 
24g at the indicated concentrations (nmol L-1). Data have been reported as the percentage of cells in the different cell cycle phases and represent 
mean values from at least three independent experiments; B) Representative western immunoblotting showing the accumulation of mitotic markers 
in cells following a 24-h exposure to the indicated amounts (nmol L-1) of paclitaxel (PTX), vinorelbine (VIN), 24e or 24g. Vinculin was used as a 
control for equal protein loading. UNT: untreated cells; C) Quantification of data from immunofluorescence and TUNEL assays (see Supporting 
Information) showing the percentage of mitotic and apoptotic cells upon the exposure to equitoxic concentrations (nmol L-1) of tested compounds, 
as indicated. Data represent mean values ± s.d. from at least three independent experiments. 
 
 
   
 
 
Figure 4. Tubulysin derivatives markedly inhibit DMPM tumor growth in vivo. A) DMPM tumor growth curves in untreated mice (CTR) and 
upon a q4dx4 i.v. administration of 24e (0.125 mg/kg,) or vinorelbine (VIN, 5 mg/kg). Data have been reported as average TV (mm3). B) 
Representative western immunoblotting showing the accumulation of MPM-2 and cyclin B and the cleavage of Caspase-3 (CPP32) in MESOII-
originated tumors removed from control animals and at the end of treatment with 24e or vinorelbine (VIN). Vinculin was used as a control for protein 
loading. CTR: tumors from untreated animals. *P<0.05; **P<0.01. 
 
The antitumor activity of the tubulysin derivative 24e was then further evaluated on in vivo DMPM tumor models, obtained 
following xenotransplantation of STO and MESOII cells into immunocompromised mice. Aqueous formulations based on 
Cremophor EL were used for 24e administration via tail vein intravenous injection. Dosing regimen of 24e was based on 
preliminary dose optimization studies in which 0.125 mg/kg administered every four days for four times (q4dx4) showed 
a significant antitumor activity in the absence of toxic effects (data not shown). The in vivo antitumor activity of 24e was 
then comparatively evaluated to that of vinorelbine, both administered at their optimal doses (i.e., 0.125 and 5 mg/Kg,[43] 
respectively) and schedule (q4dx4). Specifically, a significant (P<0.01) tumor growth delay was observed in animals 
treated with 24e compared to untreated mice in both tumor animal models, with a maximum tumor volume inhibition (TVI) 
of 64% and 77%, for STO and MESOII, respectively (Table 4 and Fig. 4A). 
 
Table 4. In vivo antitumor activity of 24e and vinorelbine (VIN) on 
human DMPM cells xenografted into immunocompromised mice. 
 Drug Dose (mg/Kg) TVI (%)[a] BWL (%)[b] 
STO 24e 0.125 64 (27)** 9 
 VIN 5 92** 7 
MESOII 24e 0.125 77 (18)** † 5 
 VIN 5 40 3 
[a] Percentage of tumor volume inhibition in treated vs. control mice. In parentheses the day on which the maximum TVI% was observed; [b] 
Percentage of body weight loss (BWL) induced by drug treatment. The highest BWL% observed is reported. **P<0.01 vs. controls; † P<0.05 vs. 
vinorelbine-treated mice (two-sided Student’s t-test). 
 
In particular, although highly significant (P<0.01), the antitumor activity of the tubulysin derivative was less pronounced 
than that exerted by vinorelbine in STO xenografts (Table 4, Fig. 4A). Interestingly, 24e showed an important antitumor 
activity also in MESOII xenografts, which, conversely, were not significantly affected in their growth by vinorelbine (Table 
4, Fig. 4A). In addition, the compound was well tolerated without any appreciable sign of toxicity and with a restrained 
effect (<10%) in terms of body weight loss, which was comparable to that observed in animals treated with vinorelbine 
(Table 4). Finally, the assessment of drug-induced changes in cell cycle-regulated factors in DMPM xenografts showed a 
marked increase in MPM-2-interacting epitopes, a pronounced accumulation of cyclin B and cleaved Caspase-3 both in 
24e- and vinorelbine-treated mice with respect to controls (Fig. 4B), thus indicating that, similarly to the vinca alkaloid, the 
tubulysin derivative induced apoptotic cell death upon mitotic arrest also in vivo at a lower dose compared to vinorelbine, 
as observed in the in vitro experimental setting. 
Conclusions 
In conclusion, we have described the first synthetic strategy that can be used to produce routinely over 200 mgs of pure 
tubulysins 24a-m per synthetic cycle. To our knowledge, this is the first method that enables the synthesis of a wide range 
of differently N-Tuv substituted tubulysins on this scale. Novel tubulysin derivatives 24a-m incorporating non-hydrolysable 
N-substituents on the Tuv fragment displayed IC50 values in the pM range on a panel of human tumor cell lines. Their 
cytotoxicity was significantly superior to that of Tubulysin A, vinorelbine, and paclitaxel, used as reference compounds. 
 
   
 
In general, the two main investigated parameters in the SAR study (fluorine or hydrogen atoms in position 4 of Tup benzyl 
moiety, and N-substituent of Tuv) had a minor effect on cytotoxicity, which remained very high throughout. Compounds 
24e and 24g were selected as lead compounds for their strongest cytotoxic activity and lowest resistance index, 
respectively, on a panel of cell lines. Surprisingly, differences between the antiproliferative activity of these tubulysins and 
reference chemotherapeutics were markedly more pronounced on LoVo/DX and MCF-7/DX cell lines characterized by in 
vitro acquired resistance to doxorubicin (DX). 
In contrast to paclitaxel and in analogy with vinorelbine, compounds 24e and 24g inhibited tubulin polymerization in STO, 
MESOII, LoVo, and LoVo/DX cell lines. A vinorelbine-like mechanism of action of these tubulysin derivatives was proved 
by assessing the capacity of 24e and 24g to antagonize the paclitaxel tubulin polymerization effect. Moreover, as for 
vinorelbine and paclitaxel, mitotic arrest and apoptosis in cancer cells were detected upon 24e and 24g cell treatments. 
These tubulysin derivatives exerted the same effect of the reference chemotherapeutics, but at significantly lower 
concentrations. 
In contrast to previously reported studies on natural tubulysins, these analogues showed effective therapeutic 
windows in vivo. In fact, assays in animal models (mice) of DMPM tumors, evidenced a significant antitumor 
activity of 24e at the dose of 0.125 mg/kg (maximum tumor volume inhibition of 64% and 77% compared to 
untreated animals for STO and MESOII, respectively). In STO xenografts, tumor growth delay induced by i.v. 
administration of 24e was less marked than that elicited by vinorelbine at the dose of 5 mg/kg. It is important to 
note that in contrast to vinorelbine (5 mg/kg), 24e (0.125 mg/kg) was able to inhibit also MESOII xenografts. In 
addition, the compound was well tolerated with no sign of general toxicity and a restrained effect (<10%) in terms 
of body weight loss. 
These results highlight the potential of these tubulysin derivatives as chemotherapeutics, particularly for treating currently 
untreatable tumors, such as diffuse malignant peritoneal mesotheliomas. In addition, these highly potent tubulysins may 
represent very promising payloads in ADCs for targeted cancer therapy. 
Experimental Section 
Chemistry. All the synthetic procedures, compounds characterizations and copies of 1H, 13C, 19F NMR spectra and MS 
analyses are included in the Supporting Information. 
Biology. Procedures and materials on in vitro assays, cell lines and antiproliferative activity assays, tubulin polymerization 
assays, in vivo studies, as well as details on methodologies (western immunoblotting flow cytometer analyses, 
fluorescence microscopy) are described in the Supporting information. 
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